Quoin Pharmaceuticals Ltd expected to post a loss of $1.61 a share - Earnings Preview

Quoin Pharmaceuticals

12/08/2026 13:48

Quoin Pharmaceuticals Ltd QNRX.OQ, QNRX.O is expected to  show no change in quarterly revenue when it reports  results on August 14 for the period ending June 30 2026

​LSEG's mean analyst estimate for Quoin Pharmaceuticals Ltd is for a loss of $1.61 per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Quoin Pharmaceuticals Ltd is $16.00, about 199.1% above its last closing price of $5.35
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-1.92
-1.93
-1.77
Beat
8.1
Dec. 31 2026
-3.34
-1.50
Beat
55
Sep. 30 2025
-4.97
-4.98
-6.71
Missed
-34.8​
Jun. 30 2025
-6.83
-7.41
-6.28
Beat
15.3
​​Mar. 31 2025
-6.26
-6.07
-6.50
Missed
-7.1
Dec. 31 2024
-16.10
-12.25
Beat
23.9​
Sep. 30 2024
-16.30
-17.27
-16.45
Beat
4.7
Jun. 30 2024
-20.98
-21.35
-13.65
Beat
36.1
This summary was machine generated August 12 at 12:48 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)